共 50 条
- [31] A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosisJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)DeAngelo, D. J.Tefferi, A.Mesa, R. A.Paley, C. S.Wadleigh, M.Snyder, D.Ondovik, M. S.Rine, J.Bhalla, K. N.
- [32] Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignanciesBLOOD, 2007, 110 (11) : 276A - 277ASpencer, AndrewPrince, MilesDeAngelo, Daniel J.Fischer, ThomasBhalla, Kapil N.Giles, Francis J.Liu, AngelaParker, KathrynLaird, GlenMasson, EricRediske, JohnScott, Jeffrey W.Ottmann, Oliver G.
- [33] A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine TumorsONCOLOGIST, 2016, 21 (07): : 785 - 786Jin, NingLubner, Sam J.Mulkerin, Daniel L.Rajguru, SaurabhCarmichael, LakeeshaChen, HerbHolen, Kyle D.LoConte, Noelle K.
- [34] Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial ResultsBIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (06) : 1074 - 1082Pidala, JosephKim, JongphilBetts, Brian C.Alsina, MelissaAyala, ErnestoFernandez, Hugo F.Field, TeresaKharfan-Dabaja, Mohamed A.Locke, Frederick L.Mishra, AsmitaNishihori, TaigaOchoa-Bayona, LeonelPerez, LiaRiches, MarcieAnasetti, Claudio
- [35] Class I and II Histone Deacetylase Inhibitor LBH589 Promotes Endocrine Differentiation in Bone Marrow Derived Human Mesenchymal Stem Cells and Suppresses Uncontrolled ProliferationEXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2021, 129 (05) : 357 - 364Schroeder, ChristophKhatri, RahulPetry, Sebastian FriedrichLinn, Thomas
- [36] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host diseaseBLOOD ADVANCES, 2020, 4 (08) : 1656 - 1669Schroeder, Mark A.Khoury, H. JeanJagasia, MadanAli, HarisSchiller, Gary J.Staser, KarlChoi, JaebokGehrs, LeahArbushites, Michael C.Yan, YingLangmuir, PeterSrinivas, NithyaPratta, MichaelPerales, Miguel-AngelChen, Yi-BinMeyers, GabrielleDiPersio, John F.
- [37] A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell CarcinomaCANCER INVESTIGATION, 2011, 29 (07) : 451 - 455Hainsworth, John D.Infante, Jeffrey R.Spigel, David R.Arrowsmith, Edward R.Boccia, Ralph V.Burris, Howard A.
- [38] Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host diseaseBone Marrow Transplantation, 2021, 56 : 1006 - 1012Natasha KekreHaesook T. KimJulia HoferVincent T. HoJohn KorethPhilippe ArmandSarah NikiforowMahasweta GooptuRizwan RomeeEdwin P. AlyeaPrashant NageshwarBrett GlotzbeckerAreej El-JawahriZachariah DeFilippRobert J. SoifferJoseph H. AntinYi-Bin ChenCorey Cutler
- [39] A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)BLOOD, 2009, 114 (22) : 130 - 131Mascarenhas, JohnWang, XiaoliRodriguez, AmelynXu, MingjiangGorman, ElaineZhang, WenyongGoldberg, Judith D.Najfeld, VesnaHoffman, Ronald
- [40] A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)BLOOD, 2014, 124 (21)Christian, BethWei, LaiSexton, JenniferJaglowski, Samantha M.Devine, Steven M.Fehniger, Todd A.Wagner-Johnston, NinaBartlett, Nancy L.Blum, Kristie A.